|
G |
AKR1C2 |
aldo-keto reductase family 1 member C2 |
increases metabolic processing |
EXP |
AKR1C2 protein results in increased metabolism of Dinoprost |
CTD |
PMID:8573067 |
|
NCBI chr10:4,987,775...5,018,000
Ensembl chr10:4,987,775...5,018,031
|
|
G |
AKR1C3 |
aldo-keto reductase family 1 member C3 |
multiple interactions |
EXP |
[AKR1C3 protein results in increased reduction of Prostaglandin D2] which results in increased chemical synthesis of Dinoprost; [Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost] |
CTD |
PMID:19997560 PMID:20036328 |
|
NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686
|
|
G |
ANXA4 |
annexin A4 |
increases expression |
ISO |
Dinoprost results in increased expression of ANXA4 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
ISO |
Dinoprost results in increased expression of ATP1A1 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 1:116,373,244...116,404,774
Ensembl chr 1:116,372,668...116,410,261
|
|
G |
ATP2B4 |
ATPase plasma membrane Ca2+ transporting 4 |
increases response to substance |
EXP |
ATP2B4 protein results in increased susceptibility to Dinoprost |
CTD |
PMID:12933703 |
|
NCBI chr 1:203,626,832...203,744,081
Ensembl chr 1:203,626,832...203,744,081
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [Dinoprost results in increased expression of PTGS2 mRNA]; CAT protein inhibits the reaction [Dinoprost results in increased localization of RELA protein] |
CTD |
PMID:20826536 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCND2 |
cyclin D2 |
decreases expression |
ISO |
Dinoprost results in decreased expression of CCND2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CES1 |
carboxylesterase 1 |
increases hydrolysis |
EXP |
CES1 protein results in increased hydrolysis of Dinoprost |
CTD |
PMID:21049984 |
|
NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337
|
|
G |
CES2 |
carboxylesterase 2 |
increases hydrolysis |
EXP |
CES2 protein results in increased hydrolysis of Dinoprost |
CTD |
PMID:21049984 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
CGB3 |
chorionic gonadotropin subunit beta 3 |
multiple interactions increases chemical synthesis |
EXP |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [CGB3 protein results in increased chemical synthesis of Dinoprost]; Indomethacin inhibits the reaction [CGB3 protein results in increased chemical synthesis of Dinoprost] |
CTD |
PMID:18555068 |
|
NCBI chr19:49,022,869...49,024,333
Ensembl chr19:49,022,869...49,024,333
|
|
G |
COL10A1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Dinoprost results in increased expression of COL10A1 mRNA; Dinoprost results in increased expression of COL10A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr 6:116,118,909...116,217,144
Ensembl chr 6:116,118,909...116,158,747
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
increases expression |
ISO |
Dinoprost results in increased expression of COL2A1 mRNA; Dinoprost results in increased expression of COL2A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
CYP19A1 |
cytochrome P450 family 19 subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Dinoprost results in decreased expression of CYP19A1 mRNA Dinoprost results in decreased expression of CYP19A1 mRNA; Dinoprost results in decreased expression of CYP19A1 protein Dinoprost promotes the reaction [GATA4 protein binds to CYP19A1 promoter] |
CTD |
PMID:11517196 PMID:15271885 |
|
NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601
|
|
G |
DLL4 |
delta like canonical Notch ligand 4 |
decreases expression |
ISO |
Dinoprost results in decreased expression of DLL4 mRNA |
CTD |
PMID:21209419 |
|
NCBI chr15:40,929,340...40,939,073
Ensembl chr15:40,929,340...40,939,073
|
|
G |
EREG |
epiregulin |
multiple interactions increases expression |
ISO |
[AL 8810 results in decreased activity of PTGFR protein] inhibits the reaction [[trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG]; [trans-10,cis-12-conjugated linoleic acid promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprost]] which results in increased expression of EREG; [trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG Dinoprost results in increased expression of EREG |
CTD |
PMID:22583689 |
|
NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749
|
|
G |
ESR1 |
estrogen receptor 1 |
increases expression |
ISO |
Dinoprost results in increased expression of ESR1 mRNA |
CTD |
PMID:21654155 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
FABP4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 protein |
CTD |
PMID:21236357 |
|
NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions affects localization |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]; Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGF2 protein] |
CTD |
PMID:15654655 PMID:16365892 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FGFR2 |
fibroblast growth factor receptor 2 |
multiple interactions affects localization decreases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]; Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]; Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGFR2 protein] Dinoprost results in decreased expression of FGFR2 mRNA |
CTD |
PMID:15654655 PMID:16365892 |
|
NCBI chr10:121,478,330...121,598,458
Ensembl chr10:121,478,332...121,598,458
|
|
G |
FOSL2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
ISO |
Dinoprost results in increased expression of FOSL2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 2:28,392,858...28,417,317
Ensembl chr 2:28,392,448...28,417,317
|
|
G |
GATA4 |
GATA binding protein 4 |
multiple interactions increases activity |
ISO |
Dinoprost promotes the reaction [GATA4 protein binds to CYP19A1 promoter] Dinoprost results in increased activity of GATA4 protein |
CTD |
PMID:15271885 |
|
NCBI chr 8:11,676,935...11,760,002
Ensembl chr 8:11,676,959...11,760,002
|
|
G |
GPX1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 gene mutant form results in increased susceptibility to Dinoprost |
CTD |
PMID:24296279 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
HMGCS2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
ISO |
Dinoprost results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 1:119,747,996...119,768,932
Ensembl chr 1:119,748,002...119,768,905
|
|
G |
HSD11B2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity decreases expression |
EXP ISO |
Dinoprost results in decreased activity of HSD11B2 protein Dinoprost results in decreased expression of HSD11B2 mRNA |
CTD |
PMID:10377029 PMID:11517196 |
|
NCBI chr16:67,429,801...67,437,553
Ensembl chr16:67,430,652...67,437,553
|
|
G |
ID1 |
inhibitor of DNA binding 1 |
decreases expression |
ISO |
Dinoprost results in decreased expression of ID1 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515
|
|
G |
ID2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
Dinoprost results in decreased expression of ID2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 2:8,682,056...8,684,461
Ensembl chr 2:8,678,845...8,684,461
|
|
G |
ID3 |
inhibitor of DNA binding 3 |
decreases expression |
ISO |
Dinoprost results in decreased expression of ID3 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 1:23,557,926...23,559,501
Ensembl chr 1:23,557,926...23,559,501
|
|
G |
IL10 |
interleukin 10 |
multiple interactions increases abundance |
EXP |
IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprost] IL10 protein results in increased abundance of Dinoprost |
CTD |
PMID:12548226 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1A |
interleukin 1 alpha |
increases abundance |
EXP |
IL1A protein results in increased abundance of Dinoprost |
CTD |
PMID:21513769 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1B |
interleukin 1 beta |
increases abundance multiple interactions |
EXP |
IL1B protein results in increased abundance of Dinoprost Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; licochalcone A inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprost] |
CTD |
PMID:12548226 PMID:16354411 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2RA |
interleukin 2 receptor subunit alpha |
increases expression |
ISO |
Dinoprost results in increased expression of IL2RA mRNA |
CTD |
PMID:11517196 |
|
NCBI chr10:6,010,689...6,062,367
Ensembl chr10:6,010,689...6,062,370
|
|
G |
IL4 |
interleukin 4 |
increases secretion multiple interactions |
EXP |
IL4 protein results in increased secretion of Dinoprost [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprost |
CTD |
PMID:23688403 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
KPNB1 |
karyopherin subunit beta 1 |
increases expression |
ISO |
Dinoprost results in increased expression of KPNB1 protein |
CTD |
PMID:16365892 |
|
NCBI chr17:47,649,919...47,685,505
Ensembl chr17:47,649,476...47,685,505
|
|
G |
LHCGR |
luteinizing hormone/choriogonadotropin receptor |
decreases expression |
ISO |
Dinoprost results in decreased expression of LHCGR mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 2:48,686,774...48,755,724
Ensembl chr 2:48,686,774...48,755,730
|
|
G |
LYPLA2 |
lysophospholipase 2 |
increases hydrolysis |
EXP |
LYPLA2 protein results in increased hydrolysis of Dinoprost analog |
CTD |
PMID:25301951 |
|
NCBI chr 1:23,791,145...23,795,539
Ensembl chr 1:23,791,110...23,795,539
|
|
G |
MAP2K1 |
mitogen-activated protein kinase kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Dinoprost results in increased phosphorylation of MAP2K1 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein] |
CTD |
PMID:24333336 |
|
NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656
|
|
G |
MAP2K2 |
mitogen-activated protein kinase kinase 2 |
increases phosphorylation multiple interactions |
ISO |
Dinoprost results in increased phosphorylation of MAP2K2 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K2 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K2 protein] |
CTD |
PMID:24333336 |
|
NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
affects localization multiple interactions increases phosphorylation |
ISO |
Dinoprost affects the localization of MAPK1 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK1 protein]; AG 1879 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; Dinoprost results in increased activity of and results in increased phosphorylation of MAPK1 protein; Egtazic Acid inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [Dinoprost results in increased activity of MAPK1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of MAPK1 protein]; Trifluoperazine inhibits the reaction [Dinoprost results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11914123 PMID:15654655 PMID:24333336 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
affects localization increases phosphorylation multiple interactions |
ISO |
Dinoprost affects the localization of MAPK3 protein Dinoprost results in increased phosphorylation of MAPK3 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK3 protein]; AG 1879 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; Dinoprost results in increased activity of and results in increased phosphorylation of MAPK3 protein; Egtazic Acid inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [Dinoprost results in increased activity of MAPK3 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of MAPK3 protein]; Trifluoperazine inhibits the reaction [Dinoprost results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [Dinoprost results in increased activity of and results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11914123 PMID:15654655 PMID:24333336 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK6 |
mitogen-activated protein kinase 6 |
increases expression |
ISO |
Dinoprost results in increased expression of MAPK6 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr15:51,971,825...52,067,375
Ensembl chr15:51,952,106...52,067,375
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
Dinoprost results in increased phosphorylation of MAPK8 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK8 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24333336 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Dinoprost results in increased phosphorylation of MAPK9 protein resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK9 protein]; SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24333336 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
Dinoprost results in increased expression of and results in increased activity of MMP2 protein |
CTD |
PMID:11719597 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Dinoprost results in increased expression of and results in increased activity of MMP9 protein |
CTD |
PMID:11719597 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
NOTCH1 |
notch receptor 1 |
decreases cleavage decreases expression |
ISO |
Dinoprost results in decreased cleavage of NOTCH1 protein Dinoprost results in decreased expression of NOTCH1 mRNA |
CTD |
PMID:21209419 |
|
NCBI chr 9:136,494,433...136,546,048
Ensembl chr 9:136,494,433...136,546,048
|
|
G |
NOTCH4 |
notch receptor 4 |
decreases expression decreases cleavage |
ISO |
Dinoprost results in decreased expression of NOTCH4 mRNA Dinoprost results in decreased cleavage of NOTCH4 protein |
CTD |
PMID:21209419 |
|
NCBI chr 6:32,194,843...32,224,067
Ensembl chr 6:32,194,843...32,224,067
|
|
G |
PDIA4 |
protein disulfide isomerase family A member 4 |
decreases expression |
ISO |
Dinoprost results in decreased expression of PDIA4 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662
|
|
G |
PLCD1 |
phospholipase C delta 1 |
increases expression |
ISO |
Dinoprost results in increased expression of PLCD1 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 3:38,007,496...38,029,642
Ensembl chr 3:38,007,496...38,029,642
|
|
G |
POR |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
Dinoprost results in increased expression of POR mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG protein |
CTD |
PMID:21236357 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PRL |
prolactin |
multiple interactions |
ISO |
[Dinoprost results in decreased abundance of Progesterone] which results in increased expression of PRL protein |
CTD |
PMID:21654155 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
PRLR |
prolactin receptor |
increases expression |
ISO |
Dinoprost results in increased expression of PRLR mRNA |
CTD |
PMID:21654155 |
|
NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487
|
|
G |
PTGDR |
prostaglandin D2 receptor |
multiple interactions |
EXP |
Dinoprost binds to and results in increased activity of PTGDR protein; Dinoprost inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 PMID:27636113 |
|
NCBI chr14:52,267,698...52,280,914
Ensembl chr14:52,267,698...52,276,724
|
|
G |
PTGER2 |
prostaglandin E receptor 2 |
multiple interactions |
EXP |
Dinoprost binds to and results in increased activity of PTGER2 protein |
CTD |
PMID:27636113 |
|
NCBI chr14:52,314,312...52,328,598
Ensembl chr14:52,314,305...52,328,598
|
|
G |
PTGFR |
prostaglandin F receptor |
increases expression multiple interactions |
ISO |
Dinoprost results in increased expression of PTGFR mRNA [AL 8810 results in decreased activity of PTGFR protein] inhibits the reaction [[trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG] |
CTD |
PMID:11517196 PMID:22583689 |
|
NCBI chr 1:78,490,974...78,540,701
Ensembl chr 1:78,303,884...78,540,701
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases abundance increases expression |
ISO EXP |
[Celecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [meloxicam results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased chemical synthesis of Dinoprost]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [trans-10,cis-12-conjugated linoleic acid results in increased chemical synthesis of Dinoprost]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [Niacin results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprost; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprost; [trans-10,cis-12-conjugated linoleic acid promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprost]] which results in increased expression of EREG PTGS2 protein results in increased abundance of Dinoprost Dinoprost results in increased expression of PTGS2 mRNA [Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [CGB3 protein results in increased chemical synthesis of Dinoprost]; Resveratrol inhibits the reaction [[Linoleic Acids, Conjugated results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprost]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost]] [Dinoprost results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprost; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased secretion of Dinoprost; CAT protein inhibits the reaction [Dinoprost results in increased expression of PTGS2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [PTGS2 protein results in increased abundance of Dinoprost] |
CTD |
PMID:18555068 PMID:18776171 PMID:18834901 PMID:20826536 PMID:20844277 PMID:21236357 PMID:22306367 PMID:22583689 PMID:27050768 More...
|
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PTK2B |
protein tyrosine kinase 2 beta |
increases expression |
ISO |
Dinoprost results in increased expression of PTK2B mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 8:27,310,506...27,459,391
Ensembl chr 8:27,311,482...27,459,391
|
|
G |
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
increases expression multiple interactions |
ISO |
Dinoprost results in increased expression of RAF1 protein modified form resveratrol inhibits the reaction [Dinoprost results in increased expression of RAF1 protein modified form]; SRT1720 inhibits the reaction [Dinoprost results in increased expression of RAF1 protein modified form] |
CTD |
PMID:24333336 |
|
NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,582,101...12,664,201
|
|
G |
RBL2 |
RB transcriptional corepressor like 2 |
decreases expression |
ISO |
Dinoprost results in decreased expression of RBL2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr16:53,434,471...53,491,648
Ensembl chr16:53,433,977...53,491,648
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
CAT protein inhibits the reaction [Dinoprost results in increased localization of RELA protein]; Dinoprost results in increased localization of and results in increased activity of RELA protein |
CTD |
PMID:20826536 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
Dinoprost results in increased expression of RUNX2 mRNA; Dinoprost results in increased expression of RUNX2 protein |
CTD |
PMID:27050768 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
SCN1B |
sodium voltage-gated channel beta subunit 1 |
increases expression |
ISO |
Dinoprost results in increased expression of SCN1B mRNA |
CTD |
PMID:11517196 |
|
NCBI chr19:35,030,470...35,040,449
Ensembl chr19:35,030,470...35,040,449
|
|
G |
SHC1 |
SHC adaptor protein 1 |
increases phosphorylation |
ISO |
Dinoprost results in increased phosphorylation of SHC1 protein alternative form |
CTD |
PMID:19168439 |
|
NCBI chr 1:154,962,298...154,974,376
Ensembl chr 1:154,962,298...154,974,395
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions |
EXP |
SIRT1 protein promotes the reaction [resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprost]] |
CTD |
PMID:20844277 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SLC22A7 |
solute carrier family 22 member 7 |
increases uptake |
EXP |
SLC22A7 protein results in increased uptake of Dinoprost |
CTD |
PMID:15901346 |
|
NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538
|
|
G |
SLC22A8 |
solute carrier family 22 member 8 |
increases transport |
ISO |
SLC22A8 protein results in increased transport of Dinoprost |
CTD |
PMID:15100168 |
|
NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
|
|
G |
SOCS1 |
suppressor of cytokine signaling 1 |
increases expression |
ISO |
Dinoprost results in increased expression of SOCS1 mRNA |
CTD |
PMID:21654155 |
|
NCBI chr16:11,254,417...11,256,204
Ensembl chr16:11,254,417...11,256,204
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
Dinoprost results in increased expression of SOCS3 mRNA |
CTD |
PMID:21654155 |
|
NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
increases expression |
ISO |
Dinoprost results in increased expression of SOX9 mRNA; Dinoprost results in increased expression of SOX9 protein |
CTD |
PMID:27050768 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
STAT5A |
signal transducer and activator of transcription 5A |
increases expression |
ISO |
Dinoprost results in increased expression of STAT5A mRNA |
CTD |
PMID:21654155 |
|
NCBI chr17:42,287,439...42,311,943
Ensembl chr17:42,287,547...42,311,943
|
|
G |
SYN2 |
synapsin II |
decreases expression |
ISO |
Dinoprost results in decreased expression of SYN2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 3:12,004,388...12,192,032
Ensembl chr 3:12,004,388...12,192,032
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
increases expression |
ISO |
Dinoprost results in increased expression of TGFB1 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
THRSP |
thyroid hormone responsive |
decreases expression |
ISO |
Dinoprost results in decreased expression of THRSP mRNA |
CTD |
PMID:10357836 |
|
NCBI chr11:78,063,861...78,068,351
Ensembl chr11:78,063,861...78,068,351
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
EXP |
Dinoprost results in decreased expression of TIMP1 protein |
CTD |
PMID:11719597 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TIMP3 |
TIMP metallopeptidase inhibitor 3 |
decreases expression |
ISO |
Dinoprost results in decreased expression of TIMP3 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041
|
|
G |
TNF |
tumor necrosis factor |
increases abundance |
EXP |
TNF protein results in increased abundance of Dinoprost |
CTD |
PMID:1993070 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein; pyrazolanthrone inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; resveratrol inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; resveratrol inhibits the reaction [Dinoprost results in increased expression of TNFRSF11B mRNA]; SB 203580 inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; SRT1720 inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein] |
CTD |
PMID:24333336 |
|
NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
increases chemical synthesis |
ISO |
UGT1A1 protein mutant form results in increased chemical synthesis of Dinoprost |
CTD |
PMID:3864191 |
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
|
|
G |
VEGFA |
vascular endothelial growth factor A |
decreases expression |
ISO |
Dinoprost results in decreased expression of VEGFA mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
YWHAE |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon |
increases expression |
ISO |
Dinoprost results in increased expression of YWHAE mRNA |
CTD |
PMID:11517196 |
|
NCBI chr17:1,344,275...1,400,222
Ensembl chr17:1,344,275...1,400,222
|
|
G |
YWHAG |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma |
increases expression |
ISO |
Dinoprost results in increased expression of YWHAG mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 7:76,326,799...76,358,991
Ensembl chr 7:76,326,799...76,358,991
|
|
G |
YWHAZ |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
increases expression |
ISO |
Dinoprost results in increased expression of YWHAZ mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 8:100,916,523...100,953,382
Ensembl chr 8:100,916,523...100,953,388
|
|
|
G |
PTGR1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
EXP |
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 9:111,549,722...111,599,647
Ensembl chr 9:111,549,722...111,599,893
|
|
|
G |
PTGR1 |
prostaglandin reductase 1 |
increases metabolic processing multiple interactions |
EXP |
PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 9:111,549,722...111,599,647
Ensembl chr 9:111,549,722...111,599,893
|
|
|
G |
APOE |
apolipoprotein E |
multiple interactions |
ISO |
[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:17118406 |
|
NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions increases abundance |
EXP |
[Lead co-treated with APP protein modified form] results in increased abundance of 8-epi-prostaglandin F2alpha APP protein modified form results in increased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:22610977 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions increases abundance increases chemical synthesis |
EXP ISO |
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Dehydroascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Resveratrol inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] pyrrolidine dithiocarbamic acid inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]; Rotenone inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:11530235 PMID:16529823 PMID:19751497 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
PAFAH2 |
platelet activating factor acetylhydrolase 2 |
affects metabolic processing multiple interactions |
ISO |
PAFAH2 protein affects the metabolism of 8-epi-prostaglandin F2alpha PAFAH2 protein affects the reaction [Carbon Tetrachloride results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:18024956 |
|
NCBI chr 1:25,959,767...25,998,063
Ensembl chr 1:25,959,767...25,998,117
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of 8-epi-prostaglandin F2alpha; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha |
CTD |
PMID:8621535 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
TBXA2R |
thromboxane A2 receptor |
multiple interactions affects response to substance |
EXP ISO |
8-epi-prostaglandin F2alpha binds to and results in increased activity of TBXA2R protein TBXA2R protein affects the susceptibility to 8-epi-prostaglandin F2alpha |
CTD |
PMID:18158556 PMID:22565502 |
|
NCBI chr19:3,594,507...3,606,875
Ensembl chr19:3,594,507...3,606,875
|
|